相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Kinome expression profiling to target new therapeutic avenues in multiple myeloma
Hugues de Boussac et al.
HAEMATOLOGICA (2020)
FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress
Roberto Ronca et al.
CANCER RESEARCH (2020)
Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer
Mitsuro Kanda et al.
MOLECULAR CANCER (2020)
Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma
Nagjie Alijaj et al.
CANCERS (2020)
NPTX2 promotes colorectal cancer growth and liver metastasis by the activation of the canonical Wnt/β-catenin pathway via FZD6
Chunjie Xu et al.
CELL DEATH & DISEASE (2019)
Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
Claire Gourzones et al.
CANCERS (2019)
BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma
Guilhem Requirand et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2019)
Molecular signatures of multiple myeloma progression through single cell RNA-Seq
Jin Sung Jang et al.
BLOOD CANCER JOURNAL (2019)
Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
Veronika Vikova et al.
THERANOSTICS (2019)
Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma
Arnold Bolomsky et al.
HAEMATOLOGICA (2018)
Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma
Arnold Bolomsky et al.
HAEMATOLOGICA (2018)
DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
Angelique Bruyer et al.
BRITISH JOURNAL OF CANCER (2018)
Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing
Georgina L. Ryland et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Multiple myeloma clonal evolution in homogeneously treated patients
Jill Corre et al.
LEUKEMIA (2018)
Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration
James M. McFarland et al.
NATURE COMMUNICATIONS (2018)
PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
Laurie Herviou et al.
CLINICAL EPIGENETICS (2018)
Presynaptic Neuronal Pentraxin Receptor Organizes Excitatory and Inhibitory Synapses
Sung-Jin Lee et al.
JOURNAL OF NEUROSCIENCE (2017)
A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma
Cristina Jimenez et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells
Robin M. Meyers et al.
NATURE GENETICS (2017)
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
L. Rasche et al.
NATURE COMMUNICATIONS (2017)
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
C. Pawlyn et al.
BLOOD CANCER JOURNAL (2017)
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
S. S. Chavan et al.
BLOOD CANCER JOURNAL (2017)
A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
A. K. Mitra et al.
BLOOD CANCER JOURNAL (2017)
Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials
Manisha Bhutani et al.
LANCET HAEMATOLOGY (2017)
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald et al.
CELL (2017)
Defining a Cancer Dependency Map
Aviad Tsherniak et al.
CELL (2017)
A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma
Allison Rosenthal et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors
A. K. Mitra et al.
LEUKEMIA (2016)
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
Niels Weinhold et al.
BLOOD (2016)
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
K. Martin Kortum et al.
BLOOD (2016)
Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma
Elena Viziteu et al.
BRITISH JOURNAL OF CANCER (2016)
Revisiting IL-6 antagonism in multiple myeloma
Thomas Matthes et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
ALTERNATIVE SPLICING OF EZH2 PRE-MRNA BY SF3B3 CONTRIBUTES TO THE TUMORIGENIC POTENTIAL OF RENAL CANCER
Haibing Xiao et al.
JOURNAL OF UROLOGY (2016)
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
Brian A. Walker et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma
Susann Weissbach et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in-17p high risk disease
Klaus M. Kortuem et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine
Jerome Moreaux et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr et al.
CANCER CELL (2014)
IMWG consensus on risk stratification in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2014)
Implications of Heterogeneity in Multiple Myeloma
Sanjay de Mel et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Modeling risk stratification in human cancer
Thierry Reme et al.
BIOINFORMATICS (2013)
Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
J. Moreaux et al.
BRITISH JOURNAL OF CANCER (2013)
Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Holly A. F. Stessman et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Metabolomics Identifies Pyrimidine Starvation as the Mechanism of 5-Aminoimidazole-4-Carboxamide-1-β-Riboside-Induced Apoptosis in Multiple Myeloma Cells
Carolyne Bardeleben et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells
Sylvanie Surget et al.
CANCER RESEARCH (2012)
Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
Jinsong Hu et al.
DISEASE MODELS & MECHANISMS (2012)
Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma
Alboukadel Kassambara et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
A gene expression signature for high-risk multiple myeloma
R. Kuiper et al.
LEUKEMIA (2012)
Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma
Alboukadel Kassambara et al.
PLOS ONE (2012)
Molecular signatures database (MSigDB) 3.0
Arthur Liberzon et al.
BIOINFORMATICS (2011)
Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration
Jerome Moreaux et al.
BLOOD (2011)
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
John D. Shaughnessy et al.
BLOOD (2011)
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines
Jerome Moreaux et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
Dirk Hose et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
Annemiek Broyl et al.
BLOOD (2010)
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
Brian A. Walker et al.
BLOOD (2010)
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor
Anne Catherine Sprynski et al.
BLOOD (2009)
Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells
Michel Jourdan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients:: A study of the intergroupe francophone du myelome
Olivier Decaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition
Wee J. Chng et al.
BLOOD (2008)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy et al.
BLOOD (2007)
The molecular classification of multiple myeloma
Fenghuang Zhan et al.
BLOOD (2006)
Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells
Emmanuelle Menoret et al.
BLOOD (2006)
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321
B Barlogie et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Molecular pathogenesis and a consequent classification of multiple myeloma
PL Bergsagel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
PL Bergsagel et al.
BLOOD (2005)
Following a TRAIL: Update on a ligand and its five receptors
FC Kimberley et al.
CELL RESEARCH (2004)
Bioconductor: open software development for computational biology and bioinformatics
RC Gentleman et al.
GENOME BIOLOGY (2004)
分享论文
